Elevance Health, Inc. $ELV Shares Bought by Commerzbank Aktiengesellschaft FI

Posted by Francis Steltz on May 17th, 2026

Commerzbank Aktiengesellschaft FI raised its position in Elevance Health, Inc. (NYSE:ELV – Free Report) by 83.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 5,431 shares of the company’s stock after acquiring an additional 2,471 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Elevance Health were worth $1,904,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Physician Wealth Advisors Inc. increased its stake in Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after buying an additional 63 shares during the period. Rossby Financial LCC increased its stake in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after buying an additional 44 shares during the period. Activest Wealth Management increased its stake in Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 34 shares during the period. ORG Partners LLC grew its stake in shares of Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after purchasing an additional 59 shares during the period. Finally, Dorato Capital Management acquired a new position in shares of Elevance Health during the 4th quarter worth $41,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ELV shares. Guggenheim upped their price target on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. JPMorgan Chase & Co. upped their price target on shares of Elevance Health from $397.00 to $411.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Mizuho lowered their price target on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 11th. Finally, Wells Fargo & Company decreased their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research report on Friday, January 30th. Thirteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and a consensus price target of $384.58.

View Our Latest Report on ELV

Elevance Health Price Performance

Elevance Health stock opened at $392.74 on Friday. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $412.96. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm’s 50-day simple moving average is $322.88 and its 200 day simple moving average is $334.02. The firm has a market capitalization of $85.29 billion, a PE ratio of 16.71, a P/E/G ratio of 2.23 and a beta of 0.66.

Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same period last year, the company earned $11.97 EPS. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts predict that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Elevance Health Company Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.